Navigation Links
Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine

SAN FRANCISCO, CA SEPTEMER 24, 2009 Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors (PPIs), did not lead to adverse events, as some prior studies had suggested. The results were presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

COGENT is the first randomized assessment of administering clopidogrel and PPIs, which reduce the production of gastric acid, on clinical events. The trial involved 3,627 patients at 393 sites. Follow up was limited due to early termination of the trial.

Internal bleeding is a common adverse effect of antiplatelet or blood thinner therapies, such as clopidogrel. The gastrointestinal tract is the most common location for this type of bleeding, which often occurs in the form of peptic ulcer disease. The purpose of the trial was to determine whether the administration of clopidogrel and omeprazole is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer disease in the setting of concomitant aspirin therapy.

The primary endpoint of the trial was a composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, and persistent pain with multiple gastric erosions, obstruction or perforation.

There was a significant reduction in gastrointestinal events with PPI use. This had not been previously demonstrated in patients receiving aspirin and clopidogrel.

"Further research is needed to define the optimal strategy to reduce GI events in patients on antithrombotic therapy, though prophylactic PPI use seems promising," said lead investigator, Deepak L. Bhatt, MD, MPH, Chief of Cardiology at VA Boston Healthcare System and Director, Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital and the VA Boston Healthcare System.


Contact: Judy Romero
Cardiovascular Research Foundation

Related medicine news :

1. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
2. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
3. Varian Medical Systems Teams With Cogent Health Solutions to Offer Case Management Software for Cancer Survivorship
4. New Heart Pump Shows Promise in Trial
5. Trial to Test Gene Therapy for Angina in Women
6. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
7. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. MDS Pharma Services Wins Award for Management of Global Malaria Trial
10. New Ovarian Cancer Drug Trial Under Way
11. Study Questions Dead-End Cancer Clinical Trials
Post Your Comments:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... solution provider of IBM software products, introduced a new company, RightSensor™ LLC, an ... and data communications capability. RightSensor™ provides a fully-managed approach for customers requiring ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Dr. Poneh Ghasri, ... New Today on September 18, 2015. The research, which was conducted at the Dental ... Sabbah and colleagues, show connections between stress during pregnancy and future dental health in ...
(Date:10/13/2015)... ... ... A child without a healthy mouth is much more likely to have an ... has joined with Global Dental Relief (GDR) to help bring dental care ... SmileCareClub will donate one clinic visit to a child in Kenya. , “When SmileCareClub ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, Inc., the ... of Synergy 2015. The annual WennSoft KEY2ACT user conference will take place from ... unite customers, partners, WennSoft team members and sponsors to facilitate the sharing of ...
(Date:10/13/2015)... ... 13, 2015 , ... T-System and Centegra Health System, a ... department visits per year, today announced the successful and rapid deployment of EV™, ... and financial outcomes. , In less than four days, Centegra Hospitals ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Calif. , Oct. 13, 2015  Asterias ... agreement with the UK-based Cell Therapy Catapult to ... AST-VAC2, Asterias, allogeneic dendritic cell immunotherapy. Under the ... scale manufacturing processes for AST-VAC2 to support advanced ... --> --> The ...
(Date:10/12/2015)... -- Use this report to: - Learn ... the medical membrane devices market. - Analyze the present ... medical membrane devices market including hemodialyzers, membrane oxygenators, intravenous ... devices. - Gain information on newly approved products, recalls ... Use this report to: - Learn about the performance, ...
(Date:10/12/2015)... Texas , Oct. 12, 2015  Luminex Corporation (NASDAQ: ... results for the third quarter ended September 30, 2015 on ... is scheduled for release after the close of trading. ... hold a conference call to discuss the operating highlights and ... on November 2, 2015, at 4:30 p.m. Eastern time. ...
Breaking Medicine Technology: